Literature DB >> 30397179

Immunotherapy and Hyperprogression: Unwanted Outcomes, Unclear Mechanism.

David A Knorr1,2, Jeffrey V Ravetch3.   

Abstract

Hyperprogression (HP) is a recently defined clinical phenomenon in which patients treated with immunotherapy paradoxically exhibit rapid tumor growth. The mechanisms of hyperprogression remain ill-defined, although recent studies in this issue point to a possible role for Fc receptors in this process.See related article by Lo Russo et al., p. 989. ©2018 American Association for Cancer Research.

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30397179      PMCID： PMC6359946          DOI： 10.1158/1078-0432.CCR-18-3144

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


  5 in total

Review 1.  Signaling by Antibodies: Recent Progress.

Authors:  Stylianos Bournazos; Taia T Wang; Rony Dahan; Jad Maamary; Jeffrey V Ravetch
Journal:  Annu Rev Immunol       Date:  2017-04-26       Impact factor: 28.527

2.  FcγRs Modulate the Anti-tumor Activity of Antibodies Targeting the PD-1/PD-L1 Axis.

Authors:  Rony Dahan; Emanuela Sega; John Engelhardt; Mark Selby; Alan J Korman; Jeffrey V Ravetch
Journal:  Cancer Cell       Date:  2015-09-14       Impact factor: 31.743

3.  Toxicity of an Fc-engineered anti-CD40 antibody is abrogated by intratumoral injection and results in durable antitumor immunity.

Authors:  David A Knorr; Rony Dahan; Jeffrey V Ravetch
Journal:  Proc Natl Acad Sci U S A       Date:  2018-10-08       Impact factor: 11.205

4.  Antibody-Fc/FcR Interaction on Macrophages as a Mechanism for Hyperprogressive Disease in Non-small Cell Lung Cancer Subsequent to PD-1/PD-L1 Blockade.

Authors:  Giuseppe Lo Russo; Massimo Moro; Michele Sommariva; Valeria Cancila; Mattia Boeri; Giovanni Centonze; Simona Ferro; Monica Ganzinelli; Patrizia Gasparini; Veronica Huber; Massimo Milione; Luca Porcu; Claudia Proto; Giancarlo Pruneri; Diego Signorelli; Sabina Sangaletti; Lucia Sfondrini; Chiara Storti; Elena Tassi; Alberto Bardelli; Silvia Marsoni; Valter Torri; Claudio Tripodo; Mario Paolo Colombo; Andrea Anichini; Licia Rivoltini; Andrea Balsari; Gabriella Sozzi; Marina Chiara Garassino
Journal:  Clin Cancer Res       Date:  2018-09-11       Impact factor: 12.531

5.  Blockade of Tumor-Expressed PD-1 promotes lung cancer growth.

Authors:  Shisuo Du; Neal McCall; Kyewon Park; Qing Guan; Paolo Fontina; Adam Ertel; Tingting Zhan; Adam P Dicker; Bo Lu
Journal:  Oncoimmunology       Date:  2018-01-29       Impact factor: 8.110
  5 in total
  15 in total

1.  Sarcopenia and high NLR are associated with the development of hyperprogressive disease after second-line pembrolizumab in patients with non-small-cell lung cancer.

Authors:  M P Petrova; I S Donev; M A Radanova; M I Eneva; E G Dimitrova; G N Valchev; V T Minchev; M S Taushanova; M V Boneva; T S Karanikolova; R B Gencheva; G A Zhbantov; A I Ivanova; C V Timcheva; B P Pavlov; V G Megdanova; B S Robev; N V Conev
Journal:  Clin Exp Immunol       Date:  2020-08-26       Impact factor: 4.330

2.  The Outcome of TGFβ Antagonism in Metastatic Breast Cancer Models In Vivo Reflects a Complex Balance between Tumor-Suppressive and Proprogression Activities of TGFβ.

Authors:  Yuan Yang; Howard H Yang; Binwu Tang; Alex Man Lai Wu; Kathleen C Flanders; Nellie Moshkovich; Douglas S Weinberg; Michael A Welsh; Jia Weng; Humberto J Ochoa; Tiffany Y Hu; Michelle A Herrmann; Jinqiu Chen; Elijah F Edmondson; R Mark Simpson; Fang Liu; Huaitian Liu; Maxwell P Lee; Lalage M Wakefield
Journal:  Clin Cancer Res       Date:  2019-10-03       Impact factor: 12.531

3.  Hyperprogression to camrelizumab in a patient with esophageal squamous cell carcinoma harboring EGFR kinase domain duplication.

Authors:  Wei Wang; Meihong Wu; Minglu Liu; Zhengqing Yan; Guoqiang Wang; Dongliang Mao; Mei Wang
Journal:  J Immunother Cancer       Date:  2020-06-23       Impact factor: 13.751

4.  Cytology cell blocks from malignant pleural effusion are good candidates for PD-L1 detection in advanced NSCLC compared with matched histology samples.

Authors:  Yinying Zou; Liming Xu; Qiusu Tang; Qihan You; Xiaoling Wang; Wei Ding; Jing Zhao; Guoping Ren
Journal:  BMC Cancer       Date:  2020-04-22       Impact factor: 4.430

5.  Transfer RNA methyltransferase gene NSUN2 mRNA expression modifies the effect of T cell activation score on patient survival in head and neck squamous carcinoma.

Authors:  Lingeng Lu; Stephen G Gaffney; Vincent L Cannataro; Jeffrey Townsend
Journal:  Oral Oncol       Date:  2019-12-27       Impact factor: 5.337

6.  Intratumoral follicular regulatory T cells curtail anti-PD-1 treatment efficacy.

Authors:  Simon Eschweiler; James Clarke; Ciro Ramírez-Suástegui; Bharat Panwar; Ariel Madrigal; Serena J Chee; Ioannis Karydis; Edwin Woo; Aiman Alzetani; Somaia Elsheikh; C J Hanley; G J Thomas; Peter S Friedmann; Tilman Sanchez-Elsner; Ferhat Ay; Christian H Ottensmeier; Pandurangan Vijayanand
Journal:  Nat Immunol       Date:  2021-06-24       Impact factor: 25.606

Review 7.  Hyperprogression After Immune-Checkpoint Inhibitor Treatment: Characteristics and Hypotheses.

Authors:  Hongjing Zang; Jinwu Peng; Hongmei Zheng; Songqing Fan
Journal:  Front Oncol       Date:  2020-04-29       Impact factor: 6.244

Review 8.  Hyperprogression Under Immune Checkpoint-Based Immunotherapy-Current Understanding, The Role of PD-1/PD-L1 Tumour-Intrinsic Signalling, Future Directions and a Potential Large Animal Model.

Authors:  Mikolaj Kocikowski; Katarzyna Dziubek; Maciej Parys
Journal:  Cancers (Basel)       Date:  2020-03-27       Impact factor: 6.639

Review 9.  How Can Immune Checkpoint Inhibitors Cause Hyperprogression in Solid Tumors?

Authors:  Morgane Denis; Michael Duruisseaux; Marie Brevet; Charles Dumontet
Journal:  Front Immunol       Date:  2020-03-20       Impact factor: 7.561

Review 10.  Biological Functions and Analytical Strategies of Sialic Acids in Tumor.

Authors:  Xiaoman Zhou; Ganglong Yang; Feng Guan
Journal:  Cells       Date:  2020-01-22       Impact factor: 6.600
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.